Company Overview and News

 
Cameco publie ses résultats du deuxième trimestre et annonce sa décision de suspendre la production à McArthur River et à Key Lake pour une durée indéterminée

2018-07-27 globenewswire
SASKATOON, Saskatchewan, 27 juill. 2018 (GLOBE NEWSWIRE) -- Cameco (TSX:CCO) (NYSE:CCJ) a communiqué aujourd’hui ses résultats financiers et opérationnels consolidés pour le deuxième trimestre clos le 30 juin 2018 conformément aux Normes internationales d’information financière (IFRS).
CCO CCJ

 
Cameco reports second quarter results and its decision to suspend production at McArthur River and Key Lake for an indeterminate duration

2018-07-25 globenewswire
SASKATOON, Saskatchewan, July 25, 2018 (GLOBE NEWSWIRE) -- Cameco (TSX:CCO) (NYSE:CCJ) today reported its consolidated financial and operating results for the second quarter ended June 30, 2018 in accordance with International Financial Reporting Standards (IFRS).
CCO CCJ

 
Cameco annonce la nouvelle heure de diffusion de ses résultats du deuxième trimestre et de sa conférence téléphonique

2018-07-23 globenewswire
SASKATOON, Saskatchewan, 23 juill. 2018 (GLOBE NEWSWIRE) -- Cameco (TSX:CCO) (NYSE:CCJ) publiera ses résultats du deuxième trimestre à la clôture des marchés le mercredi 25 juillet 2018.
CCO CCJ

 
Cameco Provides Updated Times for Q2 Results and Conference Call

2018-07-20 globenewswire
SASKATOON, Saskatchewan, July 20, 2018 (GLOBE NEWSWIRE) -- Cameco (TSX:CCO) (NYSE:CCJ) will issue its second quarter results after markets close on Wednesday, July 25, 2018.
CCO CCJ

 
Cameco répond au sujet de l’enquête initiée par le département du commerce américain dans le cadre de la « section 232 » concernant les importations d’uranium

2018-07-19 globenewswire
SASKATOON, Saskatchewan, 19 juill. 2018 (GLOBE NEWSWIRE) -- Cameco (TSX:CCO) (NYSE:CCJ) a répondu aujourd’hui à la décision prise par le département du commerce des États-Unis (DOC) de lancer une enquête afin de déterminer si la quantité et les circonstances d’importation d’uranium étranger aux États-Unis représentent une menace pour la sécurité nationale.
CCO CCJ

 
Cameco Responds to the US Department of Commerce Initiation of a Section 232 Investigation into Uranium Imports

2018-07-18 globenewswire
SASKATOON, Saskatchewan, July 18, 2018 (GLOBE NEWSWIRE) -- Cameco (TSX:CCO) (NYSE:CCJ) today responded to the decision by the United States Department of Commerce (DOC) to launch an investigation into whether the quantity and circumstances of foreign uranium imports into the US threaten to impair national security.
CCO CCJ

10
Cameco annonce l’élection de ses directeurs

2018-05-17 globenewswire
SASKATOON, Saskatchewan, 17 mai 2018 (GLOBE NEWSWIRE) -- Cameco (TSX:CCO) (NYSE:CCJ) annonce l’élection de 10 commissaires lors de sa réunion annuelle qui s’est tenue le 16 mai 2018.
CCO CCJ

11
Cameco Announces Election of Directors

2018-05-16 globenewswire - 1
SASKATOON, Saskatchewan, May 16, 2018 (GLOBE NEWSWIRE) -- Cameco (TSX:CCO) (NYSE:CCJ) has announced the election of 10 board members at its annual meeting held on May 16, 2018.
CCO CCJ

11
Cameco reports first quarter results

2018-04-27 globenewswire - 1
SASKATOON, Saskatchewan, April 27, 2018 (GLOBE NEWSWIRE) -- Cameco (TSX:CCO) (NYSE:CCJ) today reported its consolidated financial and operating results for the first quarter ended March 31, 2018 in accordance with International Financial Reporting Standards (IFRS).
CCO CCJ

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to TSX:CCO / Cameco Corp on message board site Silicon Investor.

Investor Accounting Investor Accounting Investor Accounting GALE is in good shape according to this article GALE is in good shape according to this article GALE is in good shape according to this article
Cameco Cameco Cameco 3 Free trades with scottrade use code ZXGF7585 for new acco 3 Free trades with scottrade use code ZXGF7585 for new acco 3 Free trades with scottrade use code ZXGF7585 for new acco
coastal caribbean ([email protected]) coastal caribbean ([email protected]) coastal caribbean ([email protected]) ACCO: 800America.com, Inc ACCO: 800America.com, Inc ACCO: 800America.com, Inc
NT Accounting Software (GPSI, PSQL, SOTA, TMBS) NT Accounting Software (GPSI, PSQL, SOTA, TMBS) NT Accounting Software (GPSI, PSQL, SOTA, TMBS) TOBACCO COURT * NEW LEGAL DEFENSES u0026 PUBLIC OPINION TOBACCO COURT * NEW LEGAL DEFENSES u0026 PUBLIC OPINION TOBACCO COURT * NEW LEGAL DEFENSES u0026 PUBLIC OPINION
War On Broccoli War On Broccoli War On Broccoli MFC BANCORP (u003cbu003eMXBIFu003c/bu003e) u003ciu003eSwiss bank accoun MFC BANCORP (u003cbu003eMXBIFu003c/bu003e) u003ciu003eSwiss bank accoun MFC BANCORP (u003cbu003eMXBIFu003c/bu003e) u003ciu003eSwiss bank accoun